Abstract
Peptide T, an analogue of vasoactive intestinal peptide, has improved cognitive function in patients with AIDS dementia complex in open clinical trials. me authors treated five methadone-maintained, cognitively impaired, HIV-positive patients in a double-blind crossover study for 4 weeks with 5 mg of intranasal peptide T three times a day and with placebo for 4 week. The five patients were impaired on at least two of five tests of neuropsychological function, and they had been treated with 3′-azido2′3′-dideoxythymidine (AZT) for at least 3 months prior to enrollment. These patients showed greater neuropsychological important with peptide T than with placebo, suggesting potential utility for peptide T as an adjunct to AZT treatment.